<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140616018118N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-06-10</date_registration>
      <primary_sponsor>ENT and Head &amp; Neck Research Center</primary_sponsor>
      <public_title>The Efficacy of Infra-low-frequency Transcranial Magnetic Stimulation and  Evaluation of TMS-evoked Potentials in Subjects with Chronic Tinnitus: A Double-blind, randomized, controlled trial</public_title>
      <acronym></acronym>
      <scientific_title>The Efficacy of Infra-low-frequency Transcranial Magnetic Stimulation and  Evaluation of TMS-evoked Potentials in Subjects with Chronic Tinnitus: A Double-blind, randomized, controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/16525</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: controlled randomized trial, Randomization description: Simple-individual-statistical software, Blinding description: participants are not Informed which kind of treatment They Receive.
Investigator and data analyzer don't know any information about recorded data.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Tinnitus.</hc_freetext>
      <i_freetext>Intervention 1: Patients group A: in the first and 5th sessions, 5 minutes of Sham Stimulation at a rate of 0.5 Hz, 2 minutes of merely EEG recording ,15 minutes of active TMS with a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied respectively. During these two sessions ongoing EEG is being recorded and the coil is placed at Left TemporoParietal (LTP) region. In the second, third and fourth sessions 20 minutes of only active TMS at a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied to LTP region. Intervention 2: Patients Group B: for this group the treatment-investigative sessions will be the same as patients group A, with the difference that the stimulations are applied at the Left Dorsolateral Prefrontal Cortex (Left DLPFC). Intervention 3: Normal group C: During one session, 5 minutes of Sham Stimulation at a rate of 0.5 Hz, 2 minutes of merely EEG recording ,15 minutes of active TMS with a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied respectively. During the session ongoing EEG is being recorded and the coil is placed at Left TemporoParietal region. Intervention 4: Normal group D: During one session each participant will receive interventions exactly the same as normal Group C  with the difference that the stimulations are applied at Left Dorsolateral Prefrontal Cortex (Left DLPFC).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
TMS-EEG data in tinnitus and normal subjects

When:
About January  2020

To whom:
Professors and faculty members of universities

Conditions:
Research

Where to obtain:
DR. ُSaeid Mahmoodian

How to obtain:
Contact with DR. Mahmoodian

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>DR. Saeid Mahmoudian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrat Rasoul Akram Hospital-Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6650 4294</telephone>
        <email>mahmoudian.s@iums.ac.ir</email>
        <affiliation>ENT and Head &amp; Neck Research Center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>DR. Saeid Mahmoudian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrat Rasoul Akram Hospital-Sattarkhan</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6650 4294</telephone>
        <email>mahmoudian.s@iums.ac.ir</email>
        <affiliation>ENT and Head &amp; Neck Research Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Normal hearing
Right Handed
Bilateral Tinnitus
Tinnitus Involvment more than 6 month
Informed Consent
Tinnitus Loudness more than 6 dB SL
THI Score greater than 58
VAS Score greater than 4 of 7</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of seizure, stroke, and severe physical illness
Metal implants or cardiac pacemaker
Significantly increased intracranial pressure
History of craniocerebral surgery
Pregnancy
Severe alcohol abuse
History of emotional disorder before the onset of illness
Participation in other clinical trials</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H93.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>H93.2, H93.3, H93.8, H93.9</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Patients group A: in the first and 5th sessions, 5 minutes of Sham Stimulation at a rate of 0.5 Hz, 2 minutes of merely EEG recording ,15 minutes of active TMS with a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied respectively. During these two sessions ongoing EEG is being recorded and the coil is placed at Left TemporoParietal (LTP) region. In the second, third and fourth sessions 20 minutes of only active TMS at a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied to LTP region.</i_keyword>
      <i_keyword>Patients Group B: for this group the treatment-investigative sessions will be the same as patients group A, with the difference that the stimulations are applied at the Left Dorsolateral Prefrontal Cortex (Left DLPFC).</i_keyword>
      <i_keyword>Normal group C: During one session, 5 minutes of Sham Stimulation at a rate of 0.5 Hz, 2 minutes of merely EEG recording ,15 minutes of active TMS with a rate of 0.5 Hz and an intensity of 110% resting motor threshold will be applied respectively. During the session ongoing EEG is being recorded and the coil is placed at Left TemporoParietal region.</i_keyword>
      <i_keyword>Normal group D: During one session each participant will receive interventions exactly the same as normal Group C  with the difference that the stimulations are applied at Left Dorsolateral Prefrontal Cortex (Left DLPFC).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean energy level difference among EEG frequency bands (delta, theta, alpha, ...)  before and after TMS (Transcranial Magnetic Stimulation) in tinnitus participants and normal control group. Timepoint: patients: 26 minutes of simultaneous TMS-EEG in first and last sessions                                                                                                   normal subjects: one session of 26 minutes simultaneous TMS-EEG. Method of measurement: recording EEG with active multi electrodes.</prim_outcome>
      <prim_outcome>Comparison of tinnitus severity before and after TMS. Timepoint: At the beginning and end of each session, also before and after active and sham magnetic stimulation. Method of measurement: Visual Analog Scale (VAS) for participants with  tinnitus disorder.</prim_outcome>
      <prim_outcome>Comparison of Tinnitus Questionnaire score. Timepoint: At the beginning of the first session and at the end of the last session. Method of measurement: Tinnitus Questionnaire (TQ) for participants with  tinnitus disorder.</prim_outcome>
      <prim_outcome>Comparison of Tinnitus Handicap Inventory (THI) score. Timepoint: At the beginning of the first session and at the end of the last session. Method of measurement: Tinnitus Handicap Inventory (THI) for participants with  tinnitus disorder.</prim_outcome>
      <prim_outcome>Evaluation of Amplitude, Latency, and Area under the curve of TMS-Evoked Potential Components in tinnitus participants and normal subjects. Timepoint: simultaneous with Transcranial Magnetic Stimulation. Method of measurement: By means of EEG Signal recording.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>ENT and Head &amp; Neck Research Center</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-12-10</approval_date>
        <contact_name>Ethics committee of Iran university of medical science</contact_name>
        <contact_address>Iran university of medical science, near to Milad tower, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
